|Bid||2.05 x 2200|
|Ask||2.25 x 1000|
|Day's Range||2.0600 - 2.1000|
|52 Week Range||1.6800 - 4.5500|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.89|
PORTLAND, Ore. and SAN DIEGO, Dec. 03, 2018 -- Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the.
SAN DIEGO and TORONTO, Dec. 03, 2018 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from research led by The.
“We are pleased to announce the successful re-initiation of patient dosing in our clinical trial with APTO-253, our first-in-class inhibitor of the MYC oncogene that has the potential to benefit a large patient population across various therapeutic areas, and we look forward to providing updates moving forward,” commented William G. Rice, Ph.D., Chairman, President and CEO. “As the clinical protocol requires only one patient at each of the two lowest dose levels, we have and will continue to carefully select patients for those first two dose levels.
SAN DIEGO and TORONTO, Nov. 20, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the Mississauga, Ontario-based company said it had a loss of 16 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.38. A year ago, they were trading at ...
Conference call is scheduled for tomorrow, Wednesday, November 7th at 8:00 AM ET SAN DIEGO and TORONTO, Nov. 06, 2018 -- Aptose Biosciences Inc. (“Aptose” or the.
SAN DIEGO and TORONTO, Nov. 01, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.
Conference Call to Be Held Wednesday, November 7, 2018 SAN DIEGO and TORONTO, Oct. 23, 2018 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company.
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the European Patent Office (“EPO”) has issued European Patent No. EP2940014B1 for CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. The granted patent claims various compounds, including the CG-806 compound, pharmaceutical compositions comprising the CG-806 compound, and uses for the treatment of various diseases, such as cancer. This European patent will be nationalized in, and cover, approximately forty European countries including the United Kingdom, France, Germany, Italy, Netherlands and Spain.
SAN DIEGO, Calif. and TORONTO, Sept. 25, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced ...
The Mississauga, Ontario-based company said it had a loss of 30 cents per share. The company's shares closed at $2.75. A year ago, they were trading at $1.69. _____ This story was generated by Automated ...
In this article, I’m going to take a look at Aptose Biosciences Inc’s (TSE:APS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.